Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Abstract Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80–90% of tumors)....
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d4fe26f9fdff4908953ce34c605cf410 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d4fe26f9fdff4908953ce34c605cf410 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d4fe26f9fdff4908953ce34c605cf4102021-12-02T14:23:18ZDescription of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab10.1038/s41598-021-86966-w2045-2322https://doaj.org/article/d4fe26f9fdff4908953ce34c605cf4102021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86966-whttps://doaj.org/toc/2045-2322Abstract Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80–90% of tumors). However, in T3/T4 tumors, the 3-year relapse free survival rate is only 50%. The VITAL trial aimed to assess the efficacy and safety of panitumumab in combination with this standard treatment. In this study, 27 paraffin-embedded samples from the VITAL trial and 18 samples from patients from daily clinical practice were analyzed by whole-exome sequencing and the influence of the presence of genetic variants in the response to panitumumab was studied. Having a moderate- or high-impact genetic variant in PIK3CA seemed to be related to the response to panitumumab. Furthermore, copy number variants in FGFR3, GRB2 and JAK1 were also related to the response to panitumumab. These genetic alterations have also been studied in the cohort of patients from daily clinical practice (not treated with panitumumab) and they did not have a predictive value. Therefore, in this study, a collection of genetic alterations related to the response with panitumumab was described. These results could be useful for patient stratification in new anti-EGFR clinical trials.Lucía Trilla-FuertesAngelo Gámez-PozoJoan MaurelRocio Garcia-CarboneroJaume CapdevilaLaura G-PastriánMarta MendiolaCristina PeñaRocío López-VacasMiriam CuatrecasasPilar García-AlfonsoRicardo Ramos-RuizCarlos LlorensIsmael GhanemCarles ConillVictoria Heredia-SotoÁngel Campos-BarrosJuan Ángel Fresno VaraJaime FeliuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Lucía Trilla-Fuertes Angelo Gámez-Pozo Joan Maurel Rocio Garcia-Carbonero Jaume Capdevila Laura G-Pastrián Marta Mendiola Cristina Peña Rocío López-Vacas Miriam Cuatrecasas Pilar García-Alfonso Ricardo Ramos-Ruiz Carlos Llorens Ismael Ghanem Carles Conill Victoria Heredia-Soto Ángel Campos-Barros Juan Ángel Fresno Vara Jaime Feliu Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| description |
Abstract Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80–90% of tumors). However, in T3/T4 tumors, the 3-year relapse free survival rate is only 50%. The VITAL trial aimed to assess the efficacy and safety of panitumumab in combination with this standard treatment. In this study, 27 paraffin-embedded samples from the VITAL trial and 18 samples from patients from daily clinical practice were analyzed by whole-exome sequencing and the influence of the presence of genetic variants in the response to panitumumab was studied. Having a moderate- or high-impact genetic variant in PIK3CA seemed to be related to the response to panitumumab. Furthermore, copy number variants in FGFR3, GRB2 and JAK1 were also related to the response to panitumumab. These genetic alterations have also been studied in the cohort of patients from daily clinical practice (not treated with panitumumab) and they did not have a predictive value. Therefore, in this study, a collection of genetic alterations related to the response with panitumumab was described. These results could be useful for patient stratification in new anti-EGFR clinical trials. |
| format |
article |
| author |
Lucía Trilla-Fuertes Angelo Gámez-Pozo Joan Maurel Rocio Garcia-Carbonero Jaume Capdevila Laura G-Pastrián Marta Mendiola Cristina Peña Rocío López-Vacas Miriam Cuatrecasas Pilar García-Alfonso Ricardo Ramos-Ruiz Carlos Llorens Ismael Ghanem Carles Conill Victoria Heredia-Soto Ángel Campos-Barros Juan Ángel Fresno Vara Jaime Feliu |
| author_facet |
Lucía Trilla-Fuertes Angelo Gámez-Pozo Joan Maurel Rocio Garcia-Carbonero Jaume Capdevila Laura G-Pastrián Marta Mendiola Cristina Peña Rocío López-Vacas Miriam Cuatrecasas Pilar García-Alfonso Ricardo Ramos-Ruiz Carlos Llorens Ismael Ghanem Carles Conill Victoria Heredia-Soto Ángel Campos-Barros Juan Ángel Fresno Vara Jaime Feliu |
| author_sort |
Lucía Trilla-Fuertes |
| title |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| title_short |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| title_full |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| title_fullStr |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| title_full_unstemmed |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| title_sort |
description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/d4fe26f9fdff4908953ce34c605cf410 |
| work_keys_str_mv |
AT luciatrillafuertes descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT angelogamezpozo descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT joanmaurel descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT rociogarciacarbonero descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT jaumecapdevila descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT lauragpastrian descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT martamendiola descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT cristinapena descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT rociolopezvacas descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT miriamcuatrecasas descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT pilargarciaalfonso descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT ricardoramosruiz descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT carlosllorens descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT ismaelghanem descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT carlesconill descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT victoriaherediasoto descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT angelcamposbarros descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT juanangelfresnovara descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab AT jaimefeliu descriptionofthegeneticvariantsidentifiedinacohortofpatientsdiagnosedwithlocalizedanalsquamouscellcarcinomaandtreatedwithpanitumumab |
| _version_ |
1718391454848516096 |